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Epigenet ics There are three altered epigenetic mechanisms that contribute to MM pathogenesis, by altering cell regulatory networks. 
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D  i  s  e  a  s  e      p  r  o  g  r  e  s  s  i  o  n 
  DNA methy lat ion  
•  Distinguishes non-malignant from malignant MM phenotypes. 
•  Stage-specific DNA methylation pattern: 
  Noncoding  RNAs   Histone  modi f icat ions  
Mutations in histone modifying enzymes: 
• !MMSET  and !FSFR3 " in t(4;14) cases 
 
 
 
• UTX (histone demethylase) deleted / mutated 
 
• !ANP32E (HAT inhibitor) " in add(1q) cases 
Methylates H3K36 and H4K20  
Enhances HDACs function 
  Oncogene activation 
  !histone methylation  
 !histone methylation  
MicroRNA (miRNA) dysregulation: 
A.  Downregulation " promoter hypermethylation 
•  miR129-2 " !oncogenes: CDK6, SOX4 
•  miR-194 
•  miR-34 
B.  Upregulation 
•  miR-21 " STAT3/IL-6 anti-apoptotic pathway 
•  miR-17-92 " pro-apoptotic targets (PTEN) 
•  miR-106-25 " EF21 and BCL2L11 
C.  Interaction with critical epigenetic regulators 
•  miR-29b " DNMT3b 
" Annulation of TP53 machinery  
•  miR-106b-25 " PCAF 
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Introduct ion Multiple myeloma (MM) is the most common incurable haematological malignancy. 
•  Multi-step process: premalignant phase (MGUS) " extramedullary aggressive form (PCL). 
•  Malignant plasma cells (PC) and bone marrow (BM) microenvironment interaction " !drug resistance. 
•  Manifestations: recurrent infections, anaemia, renal impairment, hypercalcemia, bone fractures and end-organ damage. 
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Multistep molecular process. Ig: Immunoglobulin; MGUS: monoclonal gammopathy of uncertain significance; PCL: plasma cell leukaemia  
Tools  
Goals  
  Understand the role of epigenetic abnormalities in 
MM and its effect in cell regulatory pathways. 
  Highlight the potential use of an epi-drug therapy as 
future treatment for MM. 
•  Bibliographic databases (Scopus and Pubmed) to search information. 
•  Bibliographic manager (Mendeley) to organize the references. 
•  Reciprocal translocations at 14q32 (IgH) " ! D-type cyclins 
•  Copy number alterations (CNAs) " del(13) and add(1q) 
G e n e t i c  
a l t e r at i o n s  
Hyperdiploid cases (≈50%)  Non-hyperdiploid cases (≈50%) 
•  Trisomies: 3,5,7,9,11,15,19 and 21 
•  Infrequent 14q32 translocations  
Secondary aberrations 
•  CNAs: del(1p), add(1q), del(13), del(17)  
•  Oncogene mutations: RAS 
•  Ig hypermutations 
•  Alterations in Rb pathway components 
•  ! Dkk1 (Wnt signalling inhibitor) 
Therapy 
A.  Immunomodulatory drugs   
  Thalidomide 
  Lenalidomide 
  Pomalidomide 
B.  Proteasome-inhibitors " Bortezomib 
C.  Other agents " Heat shock protein 90 (HSP90), IL-6 blocking therapies 
•  Apoptotic 
•  Anti-angiogenic  
•  Anti-inflammatory 
•  Inhibitors of BM-MM cells interaction 
   + 
 
Toxicity 
 
   - 
Epi -d r ugs  
Drugs acting by changing the epigenome " under development. 
  HDAC inhibitors " effect through 
 
  DNA demethylating agents " lysine demethylases and DNMT inhibitors  
  Drugs targeting proteins for epigenetic marks recognition " Ex: JQ1  
  Synthetic miRNAs " miR-29b and miR-34a 
•  Histone modifications 
•  Transcription factors (HSP90) 
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Conclusions 
Epigenetic aberrations " critical pathways alteration " MM progression.  
  Stage-specific DNA methylation pattern: 
•  Global hypomethylation " MGUS-MM transition  
 !repetitive elements demethylation " genome instability. 
•  Gene-specific hypermethylation " increasing throughout disease progression.  
  Alterations in histone-methylation patterns: 
•  Mutations in histone-modifying enzymes " !oncogenes and    TSGs. !!
  Aberrant miRNA expression: 
•  miRNAs dysregulation " alteration of critical genes and epigenetic regulators 
Advantages in treatment   but   drug resistance " incurable. 
•  Potential future therapy " epigenetic agents. 
•  Further studies 
  
•  new biomarkers 
•  novel epi-drug strategies 
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Critical pathways dysregulated by tumour suppressor genes 
(TSGs) promoter hypermethylation and miRNAs alterations. 
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